Skip to contentW
Windtree Therapeutics Inc
W
WINTWindtree Therapeutics Inc Q2 2014 · 10-Q
Revenue$1.09M$1.09M+500.5% vs Q2 2013 Net Income-$10.62M-$10.62MN/M vs Q2 2013 EPS Diluted-$1.96-$1.96N/M vs Q2 2013 Operating Income-$10,942,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Windtree Therapeutics Inc · CIK 946486 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$10,365,000N/M Margins · derivedOperating margin-1001.1%+4938.5 pt vs Q2 2013
Net margin-971.9%+3768.2 pt vs Q2 2013
ended Jun 30, 2014 · filed Aug 7, 2014 · 38 d after period end